DMTK, NASDAQ #Insider Inducement Grant #Skin DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) January 27, 2023 08:30 EST LA JOLLA, Calif.–(BUSINESS WIRE)–DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the grant to four new employees of restricted stock units representing the contingent right to receive up to an aggregate of 44,669 shares of No Comments
NASDAQ, REGN, SNY #Skin Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis January 27, 2023 00:59 EST If approved, Dupixent would be the first and only targeted medicine in the EU for these young children Recommendation based on a Phase 3 trial in children 6 months to 5 years old showing Dupixent improved skin clearance, reduced overall disease severity and improved health-related quality of life In Europe, No Comments
BCRX, NASDAQ #Skin BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema January 26, 2023 07:00 EST RESEARCH TRIANGLE PARK, N.C., Jan. 26, 2023 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the pivotal APeX-P trial evaluating oral, once-daily ORLADEYO® (berotralstat) in pediatric hereditary angioedema (HAE) patients who are 2 to <12 years of age. “Today’s announcement marks No Comments
NASDAQ, VRCA #Skin #Trending News Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum January 24, 2023 07:30 EST Potential First FDA-approved Therapy for Treatment of Molluscum Contagiosum Prevalence of Over 6 Million Molluscum Contagiosum Patients in the U.S. Alone WEST CHESTER, Pa., Jan. 24, 2023 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today No Comments
DTCFF, OTC #Skin Defence’s Melanoma Targeted Vaccine A1-Reprogrammed MSC (ARM) Cell Potency Validated January 24, 2023 03:15 EST Vancouver, British Columbia–(Newsfile Corp. – January 24, 2023) – Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company“), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the validation of its ARM vaccine candidate No Comments
JUPW, NASDAQ #Private Placement Closed #Skin Jupiter Wellness Announces Closing of $4.1 Million Registered Direct and Private Placement Offerings January 23, 2023 14:00 EST JUPITER, FL / ACCESSWIRE / January 23, 2023 / Jupiter Wellness, Inc. (“JUPW” or the “Company”) (Nasdaq:JUPW), a wellness company focused on hair, skin, and sexual wellness, today announced the closing of its previously announced registered direct offering and concurrent private placement with investors for the purchase and sale No Comments
DMTK, NASDAQ #Skin #Trending News DermTech Adds Approximately 1.2 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT) January 23, 2023 08:30 EST LA JOLLA, Calif.–(BUSINESS WIRE)–DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced favorable coverage policies from two commercial payers comprising a Blues plan in Hawaii and a physician-founded, member-focused and community-based not-for-profit health plan in New No Comments
CSTL, NASDAQ #Skin #Upcoming Presentation Castle Biosciences’ Medical Director to Present at the Precision Medicine World Conference 2023 January 23, 2023 07:00 EST FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s medical director, Matthew Goldberg, M.D., F.A.A.D., board-certified dermatologist and dermatopathologist, will present at the Precision Medicine World Conference (PMWC®) 2023, being held Jan. 25-27 in Santa No Comments
BCRX, NASDAQ #New Order #Skin BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe January 23, 2023 07:00 EST RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Swixx BioPharma AG to commercialize ORLADEYO® (berotralstat) in Central and Eastern Europe (CEE). “We continue to build partnerships with companies that have deep expertise in No Comments
IDYA, NASDAQ #New Clinical Trial Data #Phase 2 #Published Forecast #Skin #Trending News IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma January 23, 2023 06:00 EST – Initiated Phase 2 clinical trial evaluating Darovasertib as neoadjuvant treatment of uveal melanoma prior to primary interventional treatment of enucleation or radiation therapy – Clinical protocol includes neoadjuvant treatment with Darovasertib to maximum benefit up to 6 months, primary treatment, then up to 6 months of follow-up adjuvant No Comments
STEER Announces a Proposed Transaction for an $18 Million Direct Investment Involving its Digital Restaurant Supply Business (B2B Marketplace) 01/23/2023
Ra Medical Systems Announces the Presentation of Clinical Data at the European Heart Rhythm Association Congress 01/23/2023
